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ARTICLE
Multiple sclerosis risk perception and 
acceptance for Brazilian patients
Percepção e aceitação de risco em pacientes brasileiros com esclerose múltipla
Denis Bernardi Bichuetti1, Carolina Azze Franco1, Isaac Elias1, Andreia C. R. Mendonça2, Lorraine Fiama 
Diniz Carvalho2, Denise Sisterolli Diniz3, Carmen Tur4,5, Mar Tintoré4, Enedina Maria Lobato de Oliveira1
Multiple sclerosis (MS) is an inflammatory and demye-
linating disease that typically manifests in young adulthood 
and is the major cause of disability and socio-economic bur-
den in persons younger than 50 years of age in many coun-
tries1,2. Fortunately, new drugs are available and approved by 
regulatory agencies, which can reduce or even halt the dam-
age caused by MS, including the long-used disease-modi-
fying therapies (disease-modifying drugs: interferon beta 
and acetate glatiramer) and the recently-introduced natali-
zumab, fingolimod, teriflunomide, dimethyl-fumarate and 
alemtuzumab3. Nevertheless, these drugs have variable side 
effects and risk-benefit profiles that need to be suited to each 
patient’s disease severity and even personal preferences4.
Although many guidelines have been published suggesting 
how to choose the best first-line medication for each patient 
and how to monitor disease activity and drug switching3,5,6,7, 
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ABSTRACT
The perception of multiple sclerosis (MS) severity and risk associated with therapies might influence shared decision making in different 
countries. We investigated the perception of MS severity and factors associated with risk acceptance in Brazil in 96 patients with relapsing-
remitting MS using a standardized questionnaire and compared this with two European cohorts. Multiple sclerosis was perceived as a very 
severe disease and the risk of developing progressive multifocal leukoencephalopathy due to natalizumab was seen as moderate to high. 
Seventy-six percent considered a risk of 1:1,000, or higher, an impediment for natalizumab use. Older age was the only variable associated 
with higher risk acceptance and our patients showed a more conservative profile than German and Spanish patients. Our patients 
perceived MS severity and progressive multifocal leukoencephalopathy risk similarly to elsewhere, but their willingness to take risks was 
more conservative. This should be considered when discussing therapeutic options and it might have an impact on guideline adaptations.
Keywords: multiple sclerosis; natalizumab; risk-taking; risk assessment, decision making.
RESUMO
A percepção de gravidade da esclerose múltipla (EM) e riscos associado a terapias podem influenciar a escolha de tratamento em 
diferentes países. Investigamos a percepção da gravidade da EM e fatores associados à aceitação de risco em 96 pacientes com EM 
remitente-recorrentecom um questionário e comparamos com duas coortes europeias. A EM foi percebida como muito grave e o risco de 
desenvolver leucoencefalopatia multifocal progressiva devido ao natalizumabe, como moderado a alto, sendo que76% consideraram um 
risco de 1: 1.000 ou maior como impeditivo deseu uso. Idade mais avançada foi a única variável associada àaceitação de risco mais elevado 
e nossos pacientes revelaram um perfil mais conservador do que os pacientes alemães e espanhóis. Esses dados devem ser considerados 
ao discutir opções terapêuticas e pode ter impacto nas adaptações de diretrizes locais.
Palavras-chave: esclerose múltipla; natalizumabe; assunção de riscos; medição de risco; tomada de decisões.
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the shared decision-making process in MS is strongly influ-
enced by an individual’s risk perception, which is dynamic and 
influenced by the personal, emotional, social, and experien-
tial factors of both the patient and the neurologist8,9 and might 
differ from one culture to another. Indeed, it has already been 
demonstrated that the way a doctor communicates the treat-
ment options for MS might influence the patient’s decision10.
The aim of this study was to investigate the perception of 
MS severity in a cohort of Brazilian patients and access their 
knowledge of the risks associated with natalizumab, a drug with 
a well-known risk-benefit profile11, and their willingness asso-
ciated with risk acceptance of a hypothetical drug risk profile, 
and compare the results with previously published studies per-
formed with similar methodology in Germany12 and Spain13.
METHODS
We consecutively invited patients with relapsing-remit-
ting MS to answer a standardized questionnaire, aiming to get 
their impressions on the severity of MS, the risks resulting from 
natalizumab treatment and the factors involved in risk accep-
tance and decision-making. The interviews took place dur-
ing their regular clinical appointment, from January through 
October 2016 at two centers specialized in caring for peo-
ple with MS – the Neuroimmunology Clinic at Universidade 
Federal de São Paulo and the Universidade Federal de Goiás. 
This study was modeled after the work by Tur et al.13, in which 
the first author had participated, and upon previous contact 
and authorization from the lead author, with the intention 
of a cross-cultural comparison. The Ethics Committee of the 
Universidade Federal de São Paulo approved the study and the 
patients provided written informed consent to participate as 
part of an observational study on demyelinating diseases. 
Prior to answering the questionnaire, all patients were 
given a handout  containing information about MS and its 
natural clinical course, the drugs available in Brazil for treat-
ing MS and the label information for natalizumab, includ-
ing efficacy (two-year benefits defined from Phase III trial 
results as a 68% reduction in clinical relapse rate, 42% slow-
ing of disability, and 90% reduction in new brain lesions)14and 
the risk of developing progressive multifocal leukoencepha-
lopathy (PML) as presented on the Brazilian label (102 cases 
from 2006 to 2011, with risk up to 8:1,000)14. The handout was 
given to all patients and caregivers who agreed to participate 
and they were allowed adequate time to read and discuss the 
information prior to answering the questionnaire.
Knowledge of the risk for developing PML under natal-
izumab use was evaluated by five multiple choice answers, 
ranging from 1:100,000 to 1:200; and these same choices were 
again offered as indicators that the potential PML risk patients 
considered high enough to stop natalizumab or make them 
unwilling to receive the drug. Assessment of the perception 
of MS severity was performed with a survey containing visual 
analog scale questions, whose possible values ranged from 0 
to 10, as has been used previously12. Patients were asked to 
answer to what extent they judged MS to be a severe disease, 
where 0 = MS is not at all a severe disease, and 10 = MS is the 
most severe disease you can think of.
For the assessment of risk acceptance we presented 
the same five hypothetical therapeutic scenarios used by 
Tur et al.13, to maintain the uniformity of the results for further 
comparison. Briefly, patients were asked to what extent they 
would like to be prescribed a given drug if the associated annu-
alized risk of a serious secondary effect was 1:2,000,000 (very 
low risk), 1:600,000 (low risk), 1:5,000 (intermediate risk), 1:100 
(high risk), and 1:50 (very high risk). Patients answered using a 
visual analog scale, the possible values of which ranged from 0 
to 10 (0 = I would not like to receive this drug at all; 10 = I would 
like to receive this drug without any doubt). 
To help patients understand the risks associated with each 
therapeutic scenario, we also presented five events totally 
unrelated to MS, the associated risks of which were similar to 
those of the hypothetical therapeutic scenarios: to die during 
an airplane flight (1:2,000,000); to win the lottery (1:600,000); 
to die in a car accident (1:5,000); to be diagnosed with epi-
lepsy (1:100); and to be diagnosed with breast cancer (1:50, 
women’s risk). Therefore, we obtained risk-acceptance scores 
(RAS) for each therapeutic scenario, with higher RAS indicat-
ing acceptance of higher risk. The number of years of formal 
education (years of schooling) was recorded by directly asking 
the patients, considering the first year of elementary school 
in Brazil (usually at six years old). Clinical and demographic 
data were retrieved from each patient’s medical record by the 
attending neurologists and comprised age of onset, years of 
schooling, disease duration, history of disease modifying drug 
use and the expanded disability status scale(EDSS)15.
Personality traits were evaluated with the NEO Five-
Factor Inventory-Revised (NEO-FFI-R), validated for 
Brazilian Portuguese16, by means of 60 questions (12 ques-
tions per personality trait), with scores ranging from 0 to 4. 
The NEO-FFI-R explores five personality traits: neuroticism, 
extroversion, openness, agreeableness, and responsibility. 
The analysis of this questionnaire was carried out by trained 
neuropsychologists (Elias I. and Mendonça A.).
Demographic and clinical data are presented as mean 
+/- standard deviation and n (percentages). Considering the 
lower prevalence of MS in Brazil, and the later availability of 
natalizumab (late 2011)14, we did not divide the patients into 
groups by their use of or indication for natalizumab, and thus 
performed a general analysis of the whole cohort.
To evaluate if the five personality traits predicted different 
RAS, we used a multivariate general linear model (GLM). We 
evaluated each RAS independently and an additional item was 
created based on the last two questions, where we averaged 
the answers obtained for high-risk scenarios (1:100) and very 
high-risk scenarios (1:50), generating a variable called an aver-
aged RAS, which indicated the degree of acceptance of high 
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and very high treatment-associated risks, as conducted by 
Tur et al.13. For the multivariate GLM, we used the five original 
questions plus the averaged RAS as dependent variables pre-
dicted by the five personality traits as continuous covariates. 
Multivariate GLM was preferable as some of the six questions 
are strong to moderately correlated with each other, whereas 
separate linear regression would inflate false discovery rates.
In another multivariate GLM, we used the same six RAS 
measures as dependent measures predicted by sex, age, years of 
schooling, disease duration, EDSS score, and natalizumab use 
(yes/no). In both multivariate GLM (i.e., one investigating per-
sonality traits as dependent variables and the other socio-eco-
nomic and clinical features on RAS), if one of the predictors was 
shown to be statistically significant via Pillai’s trace (with an 
adopted level of significance at 0.05), we further proceeded to 
evaluate in which degree of the RAS it was a predictor. For the 
latter investigation, because there were six dependent variables, 
the level of significance was reduced to 0.05/6;in other words, in 
the last step of the GLM analysis, any of these five questions plus 
the averaged RAS could be proclaimed as significantly being pre-
dicted by the independent variables only if the pertinent p-value 
identified in the between-subjects test was less than 0.05/6 (i.e., 
lower than 0.0083)17,18. All analyses were performed with Graph 
Pad Prism version 7.0b and SPSS version 24. 
RESULTS
One hundred patients were invited and 96 answered the 
questionnaire, the latter patients being included in the final 
analysis (Table 1). All patients received at least one disease-
modifying therapy for MS during their follow-up and 20 had 
used natalizumab (Table 1). In general, patients considered 
MS to be a severe disease and understood the risks associ-
ated with natalizumab; most patients considered the risk of 
developing PML as moderate to high, and 76% considered 
1:1,000 a risk sufficient to impede its use (between 1:100,000 
and 1:200) (Table 2).
There was no evidence that personality traits could pre-
dict any of the six RAS, as the p-values for the Pillai’s trace 
were higher than 0.05 (Table 3).Given that the research ques-
tion of interest was conceptualized as a multivariate one in 
Table 1. Sociodemographic and clinical data from the 96 
participating patients.
Age (years, mean +/- SD) 39.3 (+/- 11.9)
Years of schooling (years, mean +/- SD) 12.6 (+/- 3.0)
Age at first relapse (years, mean +/-SD) 30.2 (+/- 10.5)
Disease duration (years, mean +/-SD) 9.1 (+/- 6.8)
Current treatment (n, %)
Interferon Beta 1a IM 7 (7%)
Interferon Beta 1a SC 13 (13%)
Interferon Beta 1b SC 7 (7%)





No treatment 2 (2%)
Duration of current treatment (years, mean +/-SD) 3.5 (+/- 3.4)
Number of previous treatments (n, %)*






Current or previous use of natalizumab (n, %) 20 (21%)
EDSS** at the moment of interview (mean +/- SD) 2.6 (+/- 1.5)
Progression index*** (mean +/- SD) 0.4 (+/- 0.4)
Data is presented as mean +/- standard deviation and n (%); *Previous 
treatments include: interferon-beta 1a IM, interferon-beta 1a SC, interferon-
beta 1b SC, glatiramer acetate, fingolimod, teriflunomide, natalizumab, 
IV immunoglobulin, azathioprine, cyclophosphamide or mitoxantrone; 
**Progression index: current EDSS divided by total disease duration in years; 
***EDSS: expanded disability status scale15.
Table 2. Answer profile for the 96 patients.
Disease severity perception of MS
7.3 (+/- 2.4)(0 = MS is not at all a severe disease; 10 = MS 
is the most severe disease you can think of)






Putative progressive multifocal leukoencephalopathy risk 







Opinion on the risk of developing PML under 
natalizumab use 
(VAS; 0 = very low risk, 10 = very high risk)
5.9 (+/- 2.9)
Impeditive risk for use of a theoretical drug (VAS; 0 = unlikely to 
accept, 10 = very likely to accept risk)
1:2,000,000 5.5 (+/- 3.9)
1:600,000 5.4 (+/- 3.5)
1:5,000 4.4 (+/- 3.5)
1:100 3.0 (+/- 3.4)
1:50 2.5 (+/- 3.3)
Personality traits  
Neuroticism 50.5 (+/- 9.3)
Extroversion 48.1 (+/- 9.5)
Openness 44.8 (+/- 9.4)
Agreeableness 48.4 (+/- 8.7)
Responsibility 50.3 (+/- 7.4)
Answers are displayed as mean (+/- standard deviation) when answered in 
a visual analog scale (VAS) and n (%) when answered as multiple choices.
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the first instance, and the lack of evidence that personality 
traits could influence the RAS, the univariate results (the 
between-subjects test) obtained in subsequent analyses 
were of no particular interest (i.e., evaluating which person-
ality trait would predict the RAS in each separate question). 
However, clinical and sociodemographic features evalu-
ated by Pillai’s trace showed age as statistically significant 
(Table 3). We then investigated in which RAS profiles age was 
a predictor for, and observed statistical significance for high 
RAS and the averaged RAS (high plus very high) (Table 3), 
indicating that the older the patient, the higher the scores 
for high risk (β = 0.092, p-value = 0.006) and for the averaged 
RAS (β = 0.088, p-value = 0.007), i.e., older patients tended to 
accept higher risks. When performing the model without the 
averaged RAS as an outcome, age was still significant for pre-
dicting the high risk of RAS (β = 0.092, p-value = 0.006).
The comparison between the answers profile for this 
population and two previously published cohorts with simi-
lar methodology12,13, revealed that our patients perceive MS 
severity and the risks associated with natalizumab simi-
larly, but their RAS is lower than for patients from these two 
European cohorts (Table 4 and the Figure).
DISCUSSION
This study revealed that Brazilian patients inter-
viewed in two different centers perceived MS as a very 
severe disease and understood the risks associated with 
natalizumab, a drug with a well-known risk-benefit pro-
file, but their willingness to take risks with a hypothetical 
drug was lower than patients interviewed in Germany and 
Spain12,13 (Table 4 and Figure). Moreover, only age was sig-
nificantly associated with RAS, with older patients willing 
to take higher risks. 
Although the presence of high neuroticism scores in 
patients with MS have been associated with higher levels of 
anxiety and depression19, and that individuals with MS pre-
senting with higher neuroticism tend to be more concerned 
about their illness20, none of the personality traits evaluated 
by the NEO-FFI-R predicted a RAS for this cohort. Clinical 
features, such as the EDSS, disease duration and the use of 
natalizumab also did not correlate with RAS, results similar 
to those previously reported in Spain13, reflecting the com-
plexity of the decision-making processes beyond the evalua-
tion of clinical data only. 
Table 3. Pillai’s trace for personality traits, sociodemographic and clinical features and tests of between-subjects effects for age 
as a predictor for risk acceptance scores.
Personality traits
Effect Value F Hypothesis df Error df   p-value
Neuroticism 0.009 0.159 5 86   0.977
Extroversion 0.029 0.51 5 86   0.768
Openness 0.053 0.96 5 86   0.447
Agreeableness 0.034 0.613 5 86   0.691
Responsibility 0.059 1.069 5 86   0.383
Sociodemographic and clinical features
Effect Value F Hypothesis df Error df   p-value
Sex 0.077 1.425b 5 85   0.224
Natalizumab 0.099 1.863b 5 85   0.109
Disease duration 0.099 1.874b 5 85   0.107
EDSS 0.039 0.683b 5 85   0.638
Years of schooling 0.027 0.468b 5 85   0.799
Age 0.12 2.319b 5 85   0.05
Tests of between-subjects effects for age as a predictor for risk acceptance scores
Source Risk-acceptance scores
Type III sum of 
squares df Mean square F p-value
Age
Very low 232.656 1 232.656 1.942 0.167
Low 229.368 1 229.368 1.971 0.164
Medium 36.607 1 36.607 3.147 0.08
High 84.794 1 84.794 7.871 0.006
Very high 70.181 1 70.181 6.33 0.014
Average
77.315 1 77.315 7.512 0.007
High and very high
df: degrees of freedom.
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Barcelona Natalizumab: patients that received natalizumab in the Barcelona cohort; Barcelona DMD: patients who received first-line disease modifying 
therapies in the Barcelona cohort.












1:2,000,000 (very low) 1:600,000 (low) 1:5,000 (medium) 1:100 (high) 1:50 (very high)























Table 4. Attitude towards risk acceptance in populations with distinct cultural backgrounds.
Variable
Heesen 201012 Tur 201313 Tur 201313 Bichuetti 2017 (present study)
All NTZ DMD All
Number of patients evaluated 69 114 22 96
Age (years, mean) 40 38 39 39
Disease duration (years, mean) 11 13 5 9
Previous or current natalizumab use (n, %) 69 (100%) 114 (84%) 22 (0%) 20 (21%)
Disease severity perception of MS*
8.5 (6.5-9.5) 7.0 +/- 2.0 7.6 +/- 1.8 7.3 (+/- 2.4)
median (range) mean +/- SD mean +/- SD mean +/- SD
Attitude towards risk acceptance
Natalizumab-associated PML risk** 4.5 (1.7-6.0) NA NA 5.9 (+/- 2.9)
Putative progressive multifocal leukoencephalopathy risk patients considered high enough to stop or not willing to receive natalizumab. 
1:100,000 (very low) 7%
NA NA
 -
1:5,000 (low) 10% - 
1:100 (high) 54% - 






Impeditive risk for use of a theoretical drug***
1:2,000,000 (very low)
NA
8.9 (+/- 1.9) 7.5 (+/- 2.3) 5.2 (+/-3.7)
1:600,000 (low) 8.5 (+/- 2.2) 6.3 (+/- 2.7) 5.0 (+/-3.3)
1:5,000 (medium) 7.5 (+/- 2.8) 4.8 (+/- 3.1) 3.8 (+/-2.7)
1:100 (high) 4.3 (+/- 3.5) 2.4 (+/- 2.0) 2.4 (+/-2.7)
1:50 (very high) 3.0 (+/- 3.4) 1.6 (+/- 1.8) 1.8 (+/-2.6)
1:100 + 1/50 (high and very high) 3.7 (3.4) 2.0 (+/- 1.9) 2.8 (+/- 3.3)
NTZ: patients who received natalizumab in the Barcelona cohort; DMD: patients who received first-line disease modifying therapies in the Barcelona cohort; NA: 
not available from published scientific report. VAS: visual analog scale; *0: MS is not at all a severe disease; 10: MS is the most severe disease you can think of; 
**VAS; 0: very low risk, 10: very high risk); ***VAS; 0: unlikely to accept, 10: very likely to accept
11Bichuetti DB et al. Multiple sclerosis risk perception and acceptance
The ability to take risks was not influenced by the years of 
schooling (Table 3); thus, we suppose that all patients inter-
preted the questionnaire equally, and the presence of vari-
ables not evaluated directly, such as religious beliefs, social 
class and access to private healthcare services, might influ-
ence the profile of risk acceptance in some patients. These 
and other unmeasured elements are possibly behind the 
fact that our patients also had a lower threshold for stop-
ping or not being willing to receive natalizumab, compared 
to German patients12.
Fox et al.21 performed a large survey with patients from 
the North American Research Committee on Multiple 
Sclerosis Registry (5,446 participants) using an online stan-
dard gamble paradigm: cure MS with the risk of immediate 
painless death in sleep or the two-year benefits of the use of 
natalizumab defined in the Phase III trial results as a 68% 
reduction in clinical relapse rate, 42% slowing of disability, 
and 90% reduction in new brain lesions, but with a risk of 
PML22.Although performed with a distinct methodology, 
this study revealed that three-quarters of the participants 
had a tolerance for risks lower than 1:1,000, i.e., many peo-
ple with MS are risk averse and are not willing to take high 
risks for greater benefits. Distinct from this study and Tur’s 
investigation13,the North American Research Committee 
on Multiple Sclerosis Registry showed that patients with 
greater disability tolerated greater risks for a treatment 
that would either cure their MS or slow disease progression. 
However, it seems unclear whether this is a characteristic 
of North American patients or if this result is related to the 
study design and sample size.
The measurement of risk-acceptance behaviors may vary 
between cultures and, in a huge country like Brazil, this aspect 
needs to be taken into consideration, preventing us from gen-
eralizing the current results to the whole country, especially 
as two centers do not represent the whole Brazilian popu-
lation. Our study was modeled after Tur’s work13, which is a 
little different from Heesen’s study12, restricting direct com-
parison of this cohort to the German patients. Furthermore, 
we evaluated a young patient population with a mean dis-
ease duration of only nine years, with low-to-moderate dis-
ability and with most of them having received only one or two 
disease modifying drugs. However, the opinion of patients 
with longer disease duration and greater disability could 
show more disease perception and risk-acceptance than pre-
sented here. One might say that older patients are at higher 
risk for cognitive impairment and, since this study was not 
designed to evaluate cognition, this could bias the results 
presented in Table 3. On the other hand, it is known that a 
higher EDSS score and disease duration are also related to 
cognitive impairment in MS23,24, and these two variates were 
not associated with higher risk-taking behaviors, thus reas-
suring that an older age might, indeed, be an independent 
factor for risk-acceptance.
The positivity for the John Cunningham virus ( JCV) was 
not used as a predictive variable in this study as we measured 
a hypothetical drug risk-benefit profile, and thus JCV positiv-
ity would not be related to this scenario. Furthermore, since 
we commonly test for the JCV only in patients using natali-
zumab – our only choice of a more aggressive treatment at 
the time this study was performed – the small number of par-
ticipants who used natalizumab would preclude giving sig-
nificant statistical results.
Most disease-modifying therapies are made available 
in Brazil many years after they are approved in the United 
States and the European Union. Thus, Brazilian doctors and 
patients need a few more years to get used to new medi-
cations. As examples, while natalizumab was approved 
worldwide in 2006, it was made available in Brazil only in 
late 2010 and fingolimod was made available in Brazil only 
in 2015 and to few patients due to restrictions in public 
access and reimbursement14. For these reasons, we have 
used cyclophosphamide and mitoxantrone for severe and 
breakthrough disease for longer periods than elsewhere, 
making many patients switch from natalizumab to other 
drugs very early and thus reducing its percentile of usage. 
The fact that this study was not designed to compare the 
effect of one drug versus another, as well as the variety of 
current treatments used by patients in this cohort, pre-
clude us from making an adequate and reliable comparison 
of the use of each specific drug on the risk-taking behavior, 
which would be more adequately evaluated in a larger and 
specifically-designed study.
Considering the fast-changing scenario for treating MS, 
we conclude that knowing one’s patients’ risk-taking pro-
files is important for treatment discussion and shared 
decision-making9, which may vary between different countries.
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